Changes in Hong Kong stocks | FuRui Medical Technology (01696) fell nearly 5%, and the pressure on the North American market dragged down overall performance, and the company's net profit fell 40% year on year in the first half of the year

The Zhitong Finance App learned that FuRui Medical Technology (01696) fell by nearly 5% again, and the stock fell more than 13% yesterday. As of press release, it decreased by 4.81% to HK$5.74, with a turnover of HK$16.564,500.

According to the news, FuRui Medical Technology recently announced its 2025 interim results, with revenue of US$165 million, down 1.9% year on year; parent company owners should account for profit of US$6.426 million, down 41.3% year on year. According to the announcement, the year-on-year decline in the Group's earnings during the period was mainly due to challenging conditions in the North American market, including high interest rates and weak consumption. Additionally, there was a slight delay in earnings confirmation in June due to restrictions on transportation due to regional tension. Excluding the negative factors in the North American market, compared with the same period in 2024, Furui Medical Technology's international market achieved 7.1% growth.

Shen Wan Hongyuan said that the company's North American market was impacted by high interest rates and weak consumption, and earnings declined significantly, dragging down overall performance; while the international market outside of North America achieved 7.1% growth due to direct sales office layout. The bank believes that as a leading energy source medical and aesthetic equipment company, the company relies on a direct sales network to strengthen its advantages in the Asia-Pacific region and open up a second growth curve for the injection filling business. The short-term drag in North America will not change the long-term logic, and Dashiffi's listing and combined treatment ecosystem volume are expected to drive a rebound in performance in the second half of the year.